JPMorgan Ultra Short Income ETF vs GeneDx Holdings Corp — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.46, while GeneDx Holdings Corp trades at $82.35 (market cap $2.44B). The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| JPST | WGS | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $50.78 | $167.51 |
52-Week Low | $50.40 | $34.51 |
Market Cap | — | $2.44B |
Enterprise Value | — | $2.48B |
Signals from Pluang's Aura AI — not financial advice
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.465, up 0.05% with a bearish technical signal. The ETF focuses on high-quality, short-term bonds, offering a cash alternative with consistent dividends. Recent institutional buying includes Financial Management Professionals increasing its stake by 4.7% in Q2 2026 (SEC filing, August 11, 2026).
Outlook remains stable for risk-averse investors seeking yield with low volatility. Key risks include interest rate hikes and inflation pressures, as noted in Fed commentary (Zacks Investment Research, July 31, 2026). The ETF's short duration mitigates rate sensitivity, but macroeconomic shifts could impact returns.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Trailing returns across standard periods
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →